Hormone Therapy for Male-to-Female Transition in a 46-Year-Old
For this 46-year-old transitioning to female, initiate estrogen therapy combined with an antiandrogen (spironolactone, cyproterone acetate, or GnRH agonist) to achieve testosterone levels <50 ng/dL and estradiol in the normal female range, with clinical monitoring every 3 months during the first year, then 1-2 times yearly thereafter. 1
Pre-Treatment Requirements
Before initiating hormone therapy, the following must be confirmed:
- Mental health professional diagnosis confirming gender dysphoria/gender incongruence per DSM-5 or ICD-11 criteria 1
- Eligibility criteria met: No psychiatric comorbidity interfering with treatment, demonstrated understanding of reversible and irreversible effects, and either 3 months of real-life experience OR psychotherapy 1
- Medical screening for conditions exacerbated by hormone therapy, particularly cardiovascular risk factors, thromboembolic disease risk, liver disease, and hormone-sensitive cancers 1
- Fertility counseling must be completed prior to hormone initiation 1
Hormone Regimen
Estrogen Options:
- Oral estradiol: Most commonly used
- Transdermal estradiol: Preferred if cardiovascular or thromboembolic risk factors present
- Parenteral estradiol: Alternative route 2
Antiandrogen Options (choose one):
- Spironolactone: Most common in North America
- Cyproterone acetate: Widely used internationally, though concerns exist about meningioma risk with prolonged use 2, 3
- GnRH agonists: Most effective testosterone suppression but more expensive 1, 2
Target hormone levels: Maintain estradiol in normal female physiologic range and testosterone <50 ng/dL 1, 2
Monitoring Protocol
First Year - Every 3 Months:
- Hormone levels: Testosterone, estradiol
- Prolactin: Specifically monitor in MTF patients on estrogen 1
- Liver function tests: Transient elevations occur in ~4% but usually resolve 4
- Lipid panel and cardiovascular risk assessment 1
- Clinical assessment: Blood pressure, weight, breast development, feminization progress
After First Year - Every 6-12 Months:
- Continue hormone levels, prolactin, metabolic monitoring
- Bone mineral density: If risk factors for osteoporosis exist, particularly if considering gonadectomy 1
Expected Physical Changes
Feminizing effects include 2:
- Breast development: Typically reaches maximum by 2-3 years, though may continue beyond this timeframe; most achieve Tanner stage B or greater 2
- Body composition changes: 3-5% decrease in lean body mass, increase in body fat 2
- Decreased facial/body hair
- Feminized body shape
- Muscle mass reduction: 4-5% decrease in muscle volume and cross-sectional area 2
- Hemoglobin decrease: Aligns with female reference range 2, 4
Important Caveats
Cardiovascular risk: At age 46, carefully assess for venous thromboembolism risk factors. The VTE rate is approximately 1.9% in transwomen 4. Consider transdermal estrogen if risk factors present.
Prostate screening: Continue following prostate cancer screening guidelines for biological males despite feminizing therapy 1
Breast cancer screening: Once on estrogen therapy, follow breast screening guidelines for biological women if no increased baseline risk 1
Surgery considerations: Gender-affirming surgery should only be considered after at least 1 year of consistent hormone therapy, with clearance from both the endocrinologist and mental health professional 1
Orchiectomy timing: If performed, allows reduction in antiandrogen dosing and potentially lower estrogen doses; timing varies based on individual goals 3
The Endocrine Society guidelines 1 provide the framework for this approach, with more recent evidence 2, 4 confirming safety and efficacy when following these protocols. The key is systematic monitoring to optimize feminization while minimizing adverse effects, particularly cardiovascular and metabolic complications.